With today being National Intern Day, we’re pleased to introduce you to our 2024 summer co-ops. Meet Vishu Agarwal, a sophomore at @cornelluniversity, and Matthew Palmer, a junior at @northeastern. #intern #drugdiscovery #biotech

We’re excited to share that the ACS Organic Division has awarded Larkspur scientist Morgan O’Shea a 2024 Technical Achievement in Organic Chemistry (TAOC) Award. Congrats, Morgan! #MedChem #biotech #ACSFall2024

Don’t miss our @sitccancer presentations on key tumor fitness targets: * new data on our 1st-in-class PIP4K2C protein degrader * Pin1 degradation as a promising treatment * how our ML-enabled immune evasion signature models can predict responses to cancer therapy #SITC2024

Larkspur CEO, Catherine Sabatos-Peyton, will share her perspective on the impact of the #InflationReductionAct on innovation in drug development at a @Lumanity webinar tomorrow. Register at bit.ly/3UK1UH6 #biotech #drugdiscovery

Earlier this fall, our team volunteered to pack curriculum supplies for the Science Club for Girls. We’re grateful for opportunities like this to help more girls and gender-expansive youth discover the wonders of #STEM. #culture #biotech

At Larkspur Bio, we believe in the power of community. We’re grateful to stand with @ls_cares and help make a meaningful impact this holiday season. Many thanks to our team, which collected contributions for the gift card drive for nonprofit partners. Happy holidays to all!

Our CEO, Catherine Sabatos-Peyton, will join a panel of experts discussing “Accessing Technology to Advance the Pipeline” at the Longwood Healthcare Leaders San Francisco CEO forum on Sunday, Jan. 12. More here: bit.ly/426Q3HU

Next month at the AACR Annual Meeting, we will present new research on our drug candidates targeting key cancer cell fitness genes. Abstracts here: bit.ly/3FSyh1J bit.ly/4iJxTRX #AACR25 #CancerResearch

We’re at #AACR25! Don’t miss the newest data on our cancer fitness targeting programs designed to alter the state of cancer cells and ultimately destroy tumors. Abstracts here: bit.ly/3FSyh1J bit.ly/4iJxTRX #CancerResearch #Cancer

Not to be missed from #AACR25: Larkspur presented new preclinical data on two novel programs that disrupt cancer cell fitness. Check out our findings: ✓ Pin 1 degradation bit.ly/431m9mZ ✓ PIP4K2C degradation in #ColorectalCancer bit.ly/4d5dMeY #CancerResearch

This #NationalCancerResearchMonth, we’re planning for the first clinical trial evaluating our lead candidate & feeling invigorated after sharing data at #AACR. We're proud to be a part of the cancer research community, turning scientific advancements into breakthrough treatments.

#ACSFall2025 news: we’re presenting on the discovery of LRK-4189, a 1st-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC). American Chemical Society Fall Meeting: bit.ly/47dKnOX #CancerResearch

Announcing the discovery of LRK-4189, a 1st-in-class degrader of the lipid kinase PIP4K2C for the treatment colorectal cancer (CRC). We presented at the MEDI First Time Disclosures: Breakthroughs on New Medicines session at #ACSFALL2025. bit.ly/4lCSVCm #Cancer

Thanks to Sally Church of Biotech Strategy Blog for her insightful take on why PIP4K2C stands out as a cancer fitness target and how LRK-4189, our 1st-in-class degrader of this lipid kinase, has the potential to treat MSS CRC. #Biotech #Cancer

While at the #NYSE for a Biotech CEO Sisterhood event, CEO Catherine Sabatos-Peyton discussed our cancer cell fitness approach with BiotechTV’s Brad Loncar. ➡️ Watch the full video at: bit.ly/3I9YoCZ #Cancer #Biotech #CancerResearch

Don't miss drug hunter 's case study of our lead candidate, LRK-4189. ➡️ bit.ly/4pNgHPr #biotech #cancerresearch #colorectalcancer

We’re proud to present new data at #SITC2025. We will share preclinical research on our lead candidate, LRK-4189, which we anticipate advancing into a first-in-human clinical study soon. Abstract: bit.ly/4hKCh3j #ColorectalCancer Society for Immunotherapy of Cancer

Announcing the first participant has been dosed in the Ph1 study for LRK-4189, a 1st-in-class targeted protein degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC). Learn more bit.ly/3MePHZR